<p>Squarepoint Ops LLC 在最近向證券交易委員會提交的 13F 文件中披露，在第二季度將其在 Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - 免費報告) 的持股減少了 56.0%。該機構投資者在季度內出售了 170,978 股後，持有該公司 134,395 股股票。Squarepoint Ops LLC 在最近一個季度末持有的 Ionis Pharmaceuticals 的股份約佔 0.08%，價值 5,310,000 美元。</p>
<p>獲取 <strong>Ionis Pharmaceuticals</strong> 警報：</p>
<ul>
<li>這 5 只被低估的股票準備突破嗎？</li>
</ul>
<p>其他一些對沖基金和機構投資者也買賣了該公司的股票。PNC Financial Services Group Inc. 在第二季度將其在 Ionis Pharmaceuticals 的股份增加了 3.9%。PNC Financial Services Group Inc. 現在持有 11,411 股該公司的股票，價值 451,000 美元，此前在此期間又購買了 424 股。Allworth Financial LP 在第二季度將其在 Ionis Pharmaceuticals 的持股增加了 231.8%。Allworth Financial LP 現在持有 740 股該公司的股票，價值 29,000 美元，此前又收購了 517 股。Signaturefd LLC 在第二季度將其在 Ionis Pharmaceuticals 的股份增加了 46.9%。Signaturefd LLC 現在持有 2,030 股該公司的股票，價值 80,000 美元，此前在上個季度又購買了 648 股。Corient Private Wealth LLC 在第二季度將其在 Ionis Pharmaceuticals 的持股增加了 0.3%。Corient Private Wealth LLC 現在持有 237,931 股該公司的股票，價值 9,401,000 美元，此前在上個季度又購買了 798 股。最後，Mirae Asset Global Investments Co. Ltd. 在第二季度將其在 Ionis Pharmaceuticals 的持股增加了 15.6%。Mirae Asset Global Investments Co. Ltd. 現在持有 6,148 股該公司的股票，價值 243,000 美元，此前又購買了 829 股。機構投資者持有該公司 93.86% 的股份。</p>
<h2>Ionis Pharmaceuticals 的內部買賣</h2>
<p>在 Ionis Pharmaceuticals 的其他消息中，執行副總裁 Patrick R. O'neil 於 10 月 2 日星期四出售了 64,664 股該公司的股票。股票以平均價格 67.69 美元出售，總價值為 4,377,106.16 美元。交易完成後，該執行副總裁直接持有 57,130 股公司股票，價值約 3,867,129.70 美元。這代表了其持股的 53.09% 的減少。該出售在向證券交易委員會提交的文件中披露，可以通過 SEC 網站訪問。此外，董事 Joseph H. Wender 於 12 月 1 日星期一出售了 28,000 股 Ionis Pharmaceuticals 股票。股票以平均價格 80.82 美元出售，總交易額為 2,262,960.00 美元。出售後，該董事直接持有 36,035 股公司股票，價值 2,912,348.70 美元。這筆交易是其持股的 43.73% 的減少。該出售的披露在 SEC 文件中可用。在上個季度，內部人士出售了價值 35,744,766 美元的 504,866 股公司股票。2.71% 的股票由公司內部人士持有。</p>
<h2>Ionis Pharmaceuticals 股票上漲 2.1%</h2>
<p>NASDAQ:IONS 的股票在週一開盤時為 80.82 美元。Ionis Pharmaceuticals, Inc. 的 12 個月低點為 23.95 美元，12 個月高點為 83.61 美元。該公司的流動比率為 2.79，速動比率為 2.78，債務與股本比率為 0.96。該股票的 50 天移動平均價格為 74.91 美元，200 天移動平均價格為 56.35 美元。該股票的市值為 130.9 億美元，市盈率為 -47.82，貝塔係數為 0.29。</p>
<p>Ionis Pharmaceuticals (NASDAQ:IONS - 獲取免費報告) 最近於 10 月 29 日星期三發佈了季度財報。該公司報告季度每股收益 (EPS) 為 -0.80，超過市場共識預期的 -1.15，超出 0.35。該公司季度收入為 1.5672 億美元，而分析師預期為 1.3175 億美元。Ionis Pharmaceuticals 的股本回報率為 -44.26%，淨利潤率為 -26.45%。Ionis Pharmaceuticals 本季度的收入較去年同期增長了 17.2%。去年同期，該公司每股收益為 -0.95。平均而言，股票分析師預計 Ionis Pharmaceuticals, Inc. 本年度每股收益將為 -3.5。</p>
<h2>分析師設定新目標價</h2>
<p>多位股票分析師對 IONS 股票發表了看法。摩根士丹利將 Ionis Pharmaceuticals 的目標價從 90.00 美元上調至 94.00 美元，並在 10 月 30 日星期四的研究報告中給予該股票 &#34;超配&#34; 評級。TD Cowen 將 Ionis Pharmaceuticals 的目標價從 59.00 美元上調至 99.00 美元，並在 10 月 30 日星期四的研究報告中給予該股票 &#34;買入&#34; 評級。花旗集團將 Ionis Pharmaceuticals 的目標價從 69.00 美元上調至 84.00 美元，並在 9 月 3 日星期三的研究報告中給予該公司 &#34;買入&#34; 評級。BMO Capital Markets 將 Ionis Pharmaceuticals 的評級從 &#34;市場表現&#34; 上調至 &#34;跑贏大盤&#34;，並在 9 月 3 日星期三的研究報告中將該股票的目標價從 40.00 美元上調至 70.00 美元。最後，富國銀行將 Ionis Pharmaceuticals 的目標價從 77.00 美元上調至 82.00 美元，並在 8 月 22 日星期五的報告中給予該股票 &#34;超配&#34; 評級。一位研究分析師對該股票給予了強烈買入評級，十七位給予了買入評級，三位給予了持有評級，一位給予了賣出評級。根據 MarketBeat 的數據，Ionis Pharmaceuticals 的平均評級為 &#34;適度買入&#34;，共識目標價為 84.85 美元。</p>
<p><strong>獲取我們關於 IONS 的最新報告</strong></p>
<h2>Ionis Pharmaceuticals 簡介</h2>
<p>(免費報告)</p>
<p>Ionis Pharmaceuticals, Inc. 在美國發現和開發針對 RNA 的治療藥物。該公司為兒童和成人患者提供用於脊髓性肌萎縮症（SMA）的 SPINRAZA；TEGSEDI，一種用於治療由遺傳性轉甲狀腺素澱粉樣變引起的多發性神經病的抗病毒注射劑；以及 WAYLIVRA，一種用於治療家族性乳糜微粒血癥（FCS）和家族性部分脂肪營養不良的抗病毒藥物。</p>
<h2>精選文章</h2>
<ul>
<li>五隻我們認為比 Ionis Pharmaceuticals 更好的股票</li>
<li>什麼是股息？購買最佳股息股票</li>
<li>3 只被低估的機器人股票，準備迎來鉅額收益</li>
<li>股票回購是什麼？投資者的全面指南</li>
<li>Dave &amp; Buster’s 的反轉在雙底突破後進入了 PLAY</li>
<li>如何從價值投資中獲利</li>
<li>3 只在 10 年期國債利率上升時值得購買的金融股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SU9OUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SU9OUw"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1,000 美元在 Ionis Pharmaceuticals 嗎？</h2>
<p>在考慮 Ionis Pharmaceuticals 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Ionis Pharmaceuticals 並不在名單上。</p>
<p>雖然 Ionis Pharmaceuticals 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

Ionis制藥

<p>Squarepoint Ops LLC 在第二季度減少了對 Ionis Pharmaceuticals 的持股，減持幅度為 56%，出售了 170,978 股。該公司目前持有 134,395 股，價值 531 萬美元。其他機構投資者也調整了在 Ionis 的持倉。內部人士在上個季度出售了 504,866 股，價值 3,574 萬美元。Ionis 股票上漲了 2.1%，市值為 130.9 億美元。該公司報告第三季度收入為 1.5672 億美元，同比增長 17.2%，每股淨虧損 0.80 美元，超出預期</p>

<p>Squarepoint Ops LLC reduced its holdings in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 56.0% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 134,395 shares of the company's stock after selling 170,978 shares during the quarter. Squarepoint Ops LLC owned about 0.08% of Ionis Pharmaceuticals worth $5,310,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>Squarepoint Ops LLC 在最近向證券交易委員會提交的 13F 文件中披露，在第二季度將其在 Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - 免費報告) 的持股減少了 56.0%。該機構投資者在季度內出售了 170,978 股後，持有該公司 134,395 股股票。Squarepoint Ops LLC 在最近一個季度末持有的 Ionis Pharmaceuticals 的股份約佔 0.08%，價值 5,310,000 美元。</p>
</div><p>Get <strong>Ionis Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Ionis Pharmaceuticals</strong> 警報：</p>
</div><ul>
<li>Are These 5 Undervalued Stocks Ready to Break Out?</li>
</ul>
<div class="lb-trans"><ul>
<li>這 5 只被低估的股票準備突破嗎？</li>
</ul>
</div><p>A number of other hedge funds and other institutional investors have also bought and sold shares of the business. PNC Financial Services Group Inc. raised its stake in shares of Ionis Pharmaceuticals by 3.9% during the 2nd quarter. PNC Financial Services Group Inc. now owns 11,411 shares of the company's stock valued at $451,000 after purchasing an additional 424 shares during the period. Allworth Financial LP boosted its position in shares of Ionis Pharmaceuticals by 231.8% in the second quarter. Allworth Financial LP now owns 740 shares of the company's stock valued at $29,000 after acquiring an additional 517 shares during the period. Signaturefd LLC lifted its stake in Ionis Pharmaceuticals by 46.9% in the 2nd quarter. Signaturefd LLC now owns 2,030 shares of the company's stock worth $80,000 after purchasing an additional 648 shares in the last quarter. Corient Private Wealth LLC grew its position in shares of Ionis Pharmaceuticals by 0.3% during the 2nd quarter. Corient Private Wealth LLC now owns 237,931 shares of the company's stock valued at $9,401,000 after purchasing an additional 798 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Ionis Pharmaceuticals by 15.6% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,148 shares of the company's stock worth $243,000 after purchasing an additional 829 shares during the period. Institutional investors own 93.86% of the company's stock.</p>
<div class="lb-trans"><p>其他一些對沖基金和機構投資者也買賣了該公司的股票。PNC Financial Services Group Inc. 在第二季度將其在 Ionis Pharmaceuticals 的股份增加了 3.9%。PNC Financial Services Group Inc. 現在持有 11,411 股該公司的股票，價值 451,000 美元，此前在此期間又購買了 424 股。Allworth Financial LP 在第二季度將其在 Ionis Pharmaceuticals 的持股增加了 231.8%。Allworth Financial LP 現在持有 740 股該公司的股票，價值 29,000 美元，此前又收購了 517 股。Signaturefd LLC 在第二季度將其在 Ionis Pharmaceuticals 的股份增加了 46.9%。Signaturefd LLC 現在持有 2,030 股該公司的股票，價值 80,000 美元，此前在上個季度又購買了 648 股。Corient Private Wealth LLC 在第二季度將其在 Ionis Pharmaceuticals 的持股增加了 0.3%。Corient Private Wealth LLC 現在持有 237,931 股該公司的股票，價值 9,401,000 美元，此前在上個季度又購買了 798 股。最後，Mirae Asset Global Investments Co. Ltd. 在第二季度將其在 Ionis Pharmaceuticals 的持股增加了 15.6%。Mirae Asset Global Investments Co. Ltd. 現在持有 6,148 股該公司的股票，價值 243,000 美元，此前又購買了 829 股。機構投資者持有該公司 93.86% 的股份。</p>
</div><h2>Insider Buying and Selling at Ionis Pharmaceuticals</h2>
<div class="lb-trans"><h2>Ionis Pharmaceuticals 的內部買賣</h2>
</div><p>In other Ionis Pharmaceuticals news, EVP Patrick R. O'neil sold 64,664 shares of the company's stock in a transaction on Thursday, October 2nd. The shares were sold at an average price of $67.69, for a total value of $4,377,106.16. Following the completion of the transaction, the executive vice president directly owned 57,130 shares in the company, valued at approximately $3,867,129.70. This represents a 53.09% decrease in their position. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which can be accessed through the SEC website. Also, Director Joseph H. Wender sold 28,000 shares of Ionis Pharmaceuticals stock in a transaction dated Monday, December 1st. The shares were sold at an average price of $80.82, for a total transaction of $2,262,960.00. Following the sale, the director directly owned 36,035 shares in the company, valued at $2,912,348.70. The trade was a 43.73% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 504,866 shares of company stock worth $35,744,766. 2.71% of the stock is owned by corporate insiders.</p>
<div class="lb-trans"><p>在 Ionis Pharmaceuticals 的其他消息中，執行副總裁 Patrick R. O'neil 於 10 月 2 日星期四出售了 64,664 股該公司的股票。股票以平均價格 67.69 美元出售，總價值為 4,377,106.16 美元。交易完成後，該執行副總裁直接持有 57,130 股公司股票，價值約 3,867,129.70 美元。這代表了其持股的 53.09% 的減少。該出售在向證券交易委員會提交的文件中披露，可以通過 SEC 網站訪問。此外，董事 Joseph H. Wender 於 12 月 1 日星期一出售了 28,000 股 Ionis Pharmaceuticals 股票。股票以平均價格 80.82 美元出售，總交易額為 2,262,960.00 美元。出售後，該董事直接持有 36,035 股公司股票，價值 2,912,348.70 美元。這筆交易是其持股的 43.73% 的減少。該出售的披露在 SEC 文件中可用。在上個季度，內部人士出售了價值 35,744,766 美元的 504,866 股公司股票。2.71% 的股票由公司內部人士持有。</p>
</div><h2>Ionis Pharmaceuticals Stock Up 2.1%</h2>
<div class="lb-trans"><h2>Ionis Pharmaceuticals 股票上漲 2.1%</h2>
</div><p>Shares of NASDAQ:IONS opened at $80.82 on Monday. Ionis Pharmaceuticals, Inc. has a 12-month low of $23.95 and a 12-month high of $83.61. The company has a current ratio of 2.79, a quick ratio of 2.78 and a debt-to-equity ratio of 0.96. The stock's 50-day moving average price is $74.91 and its 200-day moving average price is $56.35. The stock has a market capitalization of $13.09 billion, a P/E ratio of -47.82 and a beta of 0.29.</p>
<div class="lb-trans"><p>NASDAQ:IONS 的股票在週一開盤時為 80.82 美元。Ionis Pharmaceuticals, Inc. 的 12 個月低點為 23.95 美元，12 個月高點為 83.61 美元。該公司的流動比率為 2.79，速動比率為 2.78，債務與股本比率為 0.96。該股票的 50 天移動平均價格為 74.91 美元，200 天移動平均價格為 56.35 美元。該股票的市值為 130.9 億美元，市盈率為 -47.82，貝塔係數為 0.29。</p>
</div><p>Ionis Pharmaceuticals (NASDAQ:IONS - Get Free Report) last posted its quarterly earnings results on Wednesday, October 29th. The company reported ($0.80) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.15) by $0.35. The business had revenue of $156.72 million for the quarter, compared to analyst estimates of $131.75 million. Ionis Pharmaceuticals had a negative return on equity of 44.26% and a negative net margin of 26.45%.Ionis Pharmaceuticals's revenue for the quarter was up 17.2% compared to the same quarter last year. During the same period last year, the company earned ($0.95) EPS. On average, equities analysts anticipate that Ionis Pharmaceuticals, Inc. will post -3.5 earnings per share for the current year.</p>
<div class="lb-trans"><p>Ionis Pharmaceuticals (NASDAQ:IONS - 獲取免費報告) 最近於 10 月 29 日星期三發佈了季度財報。該公司報告季度每股收益 (EPS) 為 -0.80，超過市場共識預期的 -1.15，超出 0.35。該公司季度收入為 1.5672 億美元，而分析師預期為 1.3175 億美元。Ionis Pharmaceuticals 的股本回報率為 -44.26%，淨利潤率為 -26.45%。Ionis Pharmaceuticals 本季度的收入較去年同期增長了 17.2%。去年同期，該公司每股收益為 -0.95。平均而言，股票分析師預計 Ionis Pharmaceuticals, Inc. 本年度每股收益將為 -3.5。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析師設定新目標價</h2>
</div><p>A number of equities analysts have weighed in on IONS shares. Morgan Stanley upped their target price on Ionis Pharmaceuticals from $90.00 to $94.00 and gave the stock an &#34;overweight&#34; rating in a research note on Thursday, October 30th. TD Cowen upped their price objective on shares of Ionis Pharmaceuticals from $59.00 to $99.00 and gave the stock a &#34;buy&#34; rating in a research report on Thursday, October 30th. Citigroup raised their target price on shares of Ionis Pharmaceuticals from $69.00 to $84.00 and gave the company a &#34;buy&#34; rating in a research note on Wednesday, September 3rd. BMO Capital Markets raised shares of Ionis Pharmaceuticals from a &#34;market perform&#34; rating to an &#34;outperform&#34; rating and boosted their price target for the stock from $40.00 to $70.00 in a research note on Wednesday, September 3rd. Finally, Wells Fargo &amp; Company lifted their price objective on shares of Ionis Pharmaceuticals from $77.00 to $82.00 and gave the stock an &#34;overweight&#34; rating in a report on Friday, August 22nd. One research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Ionis Pharmaceuticals has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $84.85.</p>
<div class="lb-trans"><p>多位股票分析師對 IONS 股票發表了看法。摩根士丹利將 Ionis Pharmaceuticals 的目標價從 90.00 美元上調至 94.00 美元，並在 10 月 30 日星期四的研究報告中給予該股票 &#34;超配&#34; 評級。TD Cowen 將 Ionis Pharmaceuticals 的目標價從 59.00 美元上調至 99.00 美元，並在 10 月 30 日星期四的研究報告中給予該股票 &#34;買入&#34; 評級。花旗集團將 Ionis Pharmaceuticals 的目標價從 69.00 美元上調至 84.00 美元，並在 9 月 3 日星期三的研究報告中給予該公司 &#34;買入&#34; 評級。BMO Capital Markets 將 Ionis Pharmaceuticals 的評級從 &#34;市場表現&#34; 上調至 &#34;跑贏大盤&#34;，並在 9 月 3 日星期三的研究報告中將該股票的目標價從 40.00 美元上調至 70.00 美元。最後，富國銀行將 Ionis Pharmaceuticals 的目標價從 77.00 美元上調至 82.00 美元，並在 8 月 22 日星期五的報告中給予該股票 &#34;超配&#34; 評級。一位研究分析師對該股票給予了強烈買入評級，十七位給予了買入評級，三位給予了持有評級，一位給予了賣出評級。根據 MarketBeat 的數據，Ionis Pharmaceuticals 的平均評級為 &#34;適度買入&#34;，共識目標價為 84.85 美元。</p>
</div><p><strong>Get Our Latest Report on IONS</strong></p>
<div class="lb-trans"><p><strong>獲取我們關於 IONS 的最新報告</strong></p>
</div><h2>Ionis Pharmaceuticals Profile</h2>
<div class="lb-trans"><h2>Ionis Pharmaceuticals 簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>(免費報告)</p>
</div><p>Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.</p>
<div class="lb-trans"><p>Ionis Pharmaceuticals, Inc. 在美國發現和開發針對 RNA 的治療藥物。該公司為兒童和成人患者提供用於脊髓性肌萎縮症（SMA）的 SPINRAZA；TEGSEDI，一種用於治療由遺傳性轉甲狀腺素澱粉樣變引起的多發性神經病的抗病毒注射劑；以及 WAYLIVRA，一種用於治療家族性乳糜微粒血癥（FCS）和家族性部分脂肪營養不良的抗病毒藥物。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精選文章</h2>
</div><ul>
<li>Five stocks we like better than Ionis Pharmaceuticals</li>
<li>What Are Dividends? Buy the Best Dividend Stocks</li>
<li>3 Underrated Robotics Stocks Poised for Huge Gains</li>
<li>What is a buyback in stocks? A comprehensive guide for investors</li>
<li>Dave &amp; Buster’s Reversal Is in PLAY After Double-Bottom Breakout</li>
<li>How to Profit From Value Investing</li>
<li>3 Finance Stocks to Buy on Rising 10-Year Treasury Rates</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們認為比 Ionis Pharmaceuticals 更好的股票</li>
<li>什麼是股息？購買最佳股息股票</li>
<li>3 只被低估的機器人股票，準備迎來鉅額收益</li>
<li>股票回購是什麼？投資者的全面指南</li>
<li>Dave &amp; Buster’s 的反轉在雙底突破後進入了 PLAY</li>
<li>如何從價值投資中獲利</li>
<li>3 只在 10 年期國債利率上升時值得購買的金融股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SU9OUw" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=IONS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Ionis Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Ionis Pharmaceuticals 嗎？</h2>
</div><p>Before you consider Ionis Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Ionis Pharmaceuticals 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ionis Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Ionis Pharmaceuticals 並不在名單上。</p>
</div><p>While Ionis Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Ionis Pharmaceuticals 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Squarepoint Ops LLC 出售了 170,978 股 Ionis 製藥公司的股票，股票代碼為$IONS